RU97101109A - APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS - Google Patents

APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS

Info

Publication number
RU97101109A
RU97101109A RU97101109/14A RU97101109A RU97101109A RU 97101109 A RU97101109 A RU 97101109A RU 97101109/14 A RU97101109/14 A RU 97101109/14A RU 97101109 A RU97101109 A RU 97101109A RU 97101109 A RU97101109 A RU 97101109A
Authority
RU
Russia
Prior art keywords
gabapentin
compound
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Application number
RU97101109/14A
Other languages
Russian (ru)
Other versions
RU2168982C2 (en
Inventor
Нил Вудрафф Джоффри
С.Джи Николас
Зинг Лакбир
П.Браун Джейсон
Original Assignee
Варнер-Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/445,398 external-priority patent/US5792796A/en
Application filed by Варнер-Ламберт Компани filed Critical Варнер-Ламберт Компани
Publication of RU97101109A publication Critical patent/RU97101109A/en
Application granted granted Critical
Publication of RU2168982C2 publication Critical patent/RU2168982C2/en

Links

Claims (7)

1. Способ лечения состояния страха, включающий введение терапевтически эффективного количества соединения формулы
Figure 00000001

в которой R1 означает водород или низший алкил, а n означает 4,5 или 6 либо его фармацевтически приемлемой соли в форме дозировочной единицы млекопитающим, нуждающимся в упомянутом лечении.1. A method of treating a condition of fear, comprising administering a therapeutically effective amount of a compound of formula
Figure 00000001

in which R 1 means hydrogen or lower alkyl, and n means 4,5 or 6 or its pharmaceutically acceptable salt in the form of a dosage unit to a mammal in need of said treatment. 2. Способ лечения и/или предупреждения состояния паники, включающий введение терапевтически эффективного количества соединения формулы
Figure 00000002

в которой R1 означает водород или низший алкил, а n означает 4,5 или 6 либо его фармацевтически приемлемой соли в форме дозировочной единицы млекопитающим, нуждающимся в упомянутом лечении.2. A method of treating and / or preventing a state of panic, comprising administering a therapeutically effective amount of a compound of the formula
Figure 00000002

in which R 1 means hydrogen or lower alkyl, and n means 4,5 or 6 or its pharmaceutically acceptable salt in the form of a dosage unit to a mammal in need of said treatment. 3. Способ по п.1 или 2, по которому таким соединением является габапентин или его фармацевтически приемлемая соль. 3. The method according to claim 1 or 2, in which such a compound is gabapentin or its pharmaceutically acceptable salt. 4. Способ по п.1 или 2, согласно которому индивидуальная доза соединения или его фармацевтически приемлемой соли составляет 5 мг до 50 мг при парентеральном введении или 50 мг до 600 мг при энтеральном введении. 4. The method according to claim 1 or 2, according to which the individual dose of the compound or its pharmaceutically acceptable salt is 5 mg to 50 mg for parenteral administration or 50 mg to 600 mg for enteral administration. 5. Очищенный, связывающий габапентин белок, содержащий последовательность из первых десяти аминокислотных остатков EPFPSAVTIK, и являющийся альфа2дельта-субъединицей.5. A purified gabapentin binding protein containing the sequence of the first ten amino acid residues of EPFPSAVTIK and which is an alpha 2 delta subunit. 6. Фармакологические средства связывания с белком, связывающим [3H]-габапентин.6. Pharmacological means of binding to a protein that binds [ 3 H] -gabapentin. 7. Фармакологические средства, взаимодействующие с альфа2дельта-субъединицей Ca2+-канала.7. Pharmacological agents interacting with the alpha 2 delta subunit of the Ca 2+ channel.
RU97101109/14A 1994-07-27 1995-07-11 Method of treatment of patients with fear state or treatment and/or prophylaxis of panic state, purified protein able to bind gabapentin and pharmaceutical composition showing sedative, antipanic and anticonvulsant effects RU2168982C2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US28128594A 1994-07-27 1994-07-27
US08/281,285 1994-07-27
US08/281.285 1994-07-27
US08/445,398 US5792796A (en) 1994-07-27 1995-06-06 Methods for treating anxiety and panic
US08/445.398 1995-06-06
US08/445,398 1995-06-06

Publications (2)

Publication Number Publication Date
RU97101109A true RU97101109A (en) 1999-04-10
RU2168982C2 RU2168982C2 (en) 2001-06-20

Family

ID=26960801

Family Applications (1)

Application Number Title Priority Date Filing Date
RU97101109/14A RU2168982C2 (en) 1994-07-27 1995-07-11 Method of treatment of patients with fear state or treatment and/or prophylaxis of panic state, purified protein able to bind gabapentin and pharmaceutical composition showing sedative, antipanic and anticonvulsant effects

Country Status (18)

Country Link
EP (1) EP0804182B1 (en)
JP (1) JPH10503490A (en)
AT (1) ATE218334T1 (en)
AU (1) AU703428B2 (en)
CA (1) CA2193384C (en)
CZ (1) CZ291757B6 (en)
DE (1) DE69526972T2 (en)
DK (1) DK0804182T3 (en)
ES (1) ES2176334T3 (en)
HU (4) HU223841B1 (en)
MX (1) MX9606674A (en)
NZ (1) NZ290050A (en)
PL (1) PL187064B1 (en)
PT (1) PT804182E (en)
RO (1) RO120041B1 (en)
RU (1) RU2168982C2 (en)
SK (1) SK283711B6 (en)
WO (1) WO1996003122A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712158A (en) * 1995-06-06 1998-01-27 Warner-Lambert Company Cell line for the rapid expression of functional calcium channels
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
CA2303244C (en) 1997-10-27 2005-12-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
JP2002516312A (en) 1998-05-26 2002-06-04 ワーナー−ランバート・カンパニー Conformationally constrained amino acid compounds with affinity for the α2δ subunit of calcium channels
FR2781793B1 (en) * 1998-08-03 2001-07-20 Prographarm Lab PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES
AU7904500A (en) * 1999-09-16 2001-04-17 Warner-Lambert Company Method for the screening of alpha2delta-1 subunit binding ligands
RU2377234C2 (en) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Treatment or prevention of restless legs syndrome with using promedicines of gaba analogues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
US5189026A (en) * 1991-06-07 1993-02-23 Fractal Laboratories, Inc. Treatment of human diseases involving dysregulation or dysfunction of the nervous system
RU2140901C1 (en) * 1992-05-20 1999-11-10 Нортвестерн Юниверсити Analogs of gamma-aminobutyric acid, method of their synthesis, method of treatment and pharmaceutical composition

Similar Documents

Publication Publication Date Title
RU99101790A (en) METHOD FOR TREATING URINE INCOMPOSITION USING (S) -OXIBUTININ AND (S) -DESETHYLOXIBUTININ
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
RU96115200A (en) 2,4-DISULFOFENYLBUTILNITRON, ITS SALT AND THEIR APPLICATION AS PHARMACEUTICAL SPIN TRAPS
CO5261582A1 (en) VALDECOXIB COMPOSITIONS
DK1196430T3 (en) Purification and stabilization of peptides and proteins in pharmaceutical agents
SE8306367L (en) ANTIDIURETICALLY EFFECTIVE PHARMACEUTICAL PREPARATION
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU97101109A (en) APPLICATION OF GABAPENTIN FOR TREATMENT OF FEAR AND PANIC CONDITIONS
RU94034109A (en) AGENT FOR THE TREATMENT OF THE STATE OF ALARM
ATE361098T1 (en) PREVENTION AND TREATMENT OF HYPERGASTRINEMIA
KR970061249A (en) Compositions for Treating or Preventing Osteoporosis
Shah et al. Spinal and supraspinal effects of pertussis toxin on opioid analgesia
RU2005105691A (en) Oral Administration of Calcitonin
RU96103685A (en) 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION
RU99100703A (en) MODIFIED FORM OF HYDROCHLORIDE R (-) - N - (4,4-DI (3-METHYL-THIEN-2-IL) BUT-3-ENYL) -NIPECOTHIC ACID
RU2002111000A (en) A method for the therapeutic treatment of ectopic proliferation of endometrial tissue, chronic pelvic pain and fallopian obstruction, pharmaceutical composition and antagonist LHRH drug for this treatment (options)
KR900701278A (en) Bile acids for the treatment of viral infections
US5055449A (en) Vincristine-containing product
RU95112520A (en) APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS
KR940005667A (en) Linear peptide
KR950700063A (en) Brofaromine as an agent for treating post-traumatic stress
EP0790250A3 (en) Inhibitors of biogenic amine transporters
JP3173008B2 (en) Liver disease treatment
RU99122954A (en) PEPTIDE FRAGMENTS OF MYELIN'S BASIC PROTEIN, PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS AND THE APPLICATION OF DATA OF COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
KR890701111A (en) Treatment of dyslipidemia in humans